
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists are effective medications for people with type 2 diabetes because they enhance insulin release in response to meals and dampen the liver’s production of glucose. They are typically introduced when oral treatments like metformin do not fully control blood sugar or when additional benefits beyond glucose lowering are desired. Some GLP-1 therapies have also been associated with reduced rates of heart attack, stroke, and cardiovascular death in patients who have diabetes and pre existing heart disease.
In non diabetic patients, GLP-1 agonists such as Wegovy and Saxenda are FDA approved as part of a comprehensive strategy for weight loss. By increasing satiety and reducing overall appetite, these medications help individuals eat less while feeling more satisfied, which supports consistent calorie reduction. Clinical research has found that combining GLP-1 medication with lifestyle changes leads to notable and long term weight loss in many patients.
GLP-1 receptor agonists manage blood sugar by stimulating insulin release after eating and reducing glucagon output, which in turn limits the liver’s release of stored glucose. This coordinated mechanism helps prevent sharp surges in blood glucose and improves day to day glycemic stability. Because they act primarily when blood sugar is high, these drugs carry a lower risk of hypoglycemia than many older therapies.
GLP-1 therapy plays a crucial role in achieving sustainable weight loss and long term weight control. It slows stomach emptying and communicates with the brain to heighten satiety, which in turn lowers hunger and helps individuals naturally reduce their calorie intake. Clinical data have shown that medications such as liraglutide, semaglutide, and tirzepatide can result in significant and ongoing weight loss when they are used alongside healthy lifestyle habits.



GLP-1/GIP co-agonists activate both GLP-1 and GIP receptors to enhance insulin secretion and appetite control more effectively than GLP-1 alone. These medications provide a more comprehensive approach to managing blood sugar and hunger, making them a promising therapy for managing obesity and diabetes.
GLP-1/glucagon co-agonists work on both GLP-1 and glucagon receptors, improving weight loss and boosting energy metabolism while maintaining lean muscle mass, which supports overall metabolic health.
You may want to consider GLP-1 therapy if:

